Studies show that patients who are obese or overweight using injectable GLP-1 agonist medications for weight loss, combined with diet and exercise, achieve weight loss of approximately 6% of their body weight at 4 months, 9% at 6 months, and 13% at 12 months
Illustration of a semaglutide peptide (blue) bound to its target glucagon-like peptide-1 (GLP-1, light pink)
Common side effects include nausea, vomiting, diarrhea, constipation, and indigestion particularly when first starting the medication or adjusting dosages
"Because I've avoided the mirror for so long, now I'm trying to stare more into it, stare more deeply and see that reflection and let it catch up to my brain."
Patients with metabolic syndrome see outsized benefits
That pattern has already started with semaglutide and is expected for other GLP-1s.[7][17] 3